Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $4.66 in the prior trading day, Geron Corp. (NASDAQ: GERN) closed at $4.69, up 0.64%. In other words, the price has increased by $0.64 from its previous closing price. On the day, 14.45 million shares were traded. GERN stock price reached its highest trading level at $4.855 during the session, while it also had its lowest trading level at $4.65.
Ratios:
Our goal is to gain a better understanding of GERN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.67 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.04.
On April 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $10.
Needham reiterated its Buy rating for the stock on March 15, 2024, while the target price for the stock was revised from $4 to $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 08 ’24 when GRETHLEIN ANDREW J sold 674,348 shares for $4.56 per share. The transaction valued at 3,073,004 led to the insider holds 0 shares of the business.
Kapur Anil sold 421,875 shares of GERN for $1,959,609 on Jun 10 ’24. The EVP, Corp Strategy & CCO now owns 0 shares after completing the transaction at $4.64 per share. On Jun 10 ’24, another insider, Feller Faye, who serves as the EVP, Chief Medical Officer of the company, sold 287,900 shares for $4.63 each. As a result, the insider received 1,334,129 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GERN now has a Market Capitalization of 2781793792 and an Enterprise Value of 2425271552. For the stock, the TTM Price-to-Sale (P/S) ratio is 5349.58 while its Price-to-Book (P/B) ratio in mrq is 8.04. Its current Enterprise Value per Revenue stands at 4663.984 whereas that against EBITDA is -11.575.
Stock Price History:
Over the past 52 weeks, GERN has reached a high of $5.34, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is 8.47%, while the 200-Day Moving Average is calculated to be 61.66%.
Shares Statistics:
The stock has traded on average 11.69M shares per day over the past 3-months and 10374840 shares per day over the last 10 days, according to various share statistics. A total of 544.91M shares are outstanding, with a floating share count of 500.46M. Insiders hold about 15.62% of the company’s shares, while institutions hold 58.26% stake in the company. Shares short for GERN as of 1721001600 were 44657819 with a Short Ratio of 3.82, compared to 1718323200 on 54116763. Therefore, it implies a Short% of Shares Outstanding of 44657819 and a Short% of Float of 7.57.
Earnings Estimates
The firm’s stock currently is rated by 7.0 analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.11, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.08 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.31 and -$0.42 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.17, with 6.0 analysts recommending between -$0.02 and -$0.22.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $15.9M. There is a high estimate of $22.5M for the next quarter, whereas the lowest estimate is $5.2M.
A total of 7 analysts have provided revenue estimates for GERN’s current fiscal year. The highest revenue estimate was $73.29M, while the lowest revenue estimate was $24.8M, resulting in an average revenue estimate of $51.28M. In the same quarter a year ago, actual revenue was $237kBased on 7 analysts’ estimates, the company’s revenue will be $263.56M in the next fiscal year. The high estimate is $360.44M and the low estimate is $189.61M.
